Form 4: AbbVie Executive Sells Shares for Tax Obligations
Insider Transaction Report
AbbVie's EVP, Chief Business and Strategy Officer, Nicholas Donoghoe, disposed of 12,874 shares of common stock to cover tax withholding obligations.
Summary
- Nicholas Donoghoe, Executive Vice President, Chief Business and Strategy Officer of AbbVie Inc. (ABBV), reported a transaction.
- On February 27, 2026, Donoghoe disposed of 12,874 shares of AbbVie Common Stock, $0.01 par value.
- The disposition was made at a price of $232.08 per share.
- The transaction code 'F' indicates a disposition to the issuer to satisfy tax withholding obligations.
- Following this transaction, Donoghoe beneficially owns 74,430 shares of AbbVie Common Stock directly.
- The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It represents a standard administrative transaction for tax purposes and does not indicate any fundamental change in the company's operations or the executive's confidence.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
StockSavvy.ai notes that Form 4 filings detailing the disposition of shares for tax withholding purposes are a routine occurrence for executives who receive equity compensation. These transactions are typically pre-planned under Rule 10b5-1 plans and do not usually signal a change in management's outlook on the company's prospects.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Transaction Plan Disclosure | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 02/27/2026 | Indicates a pre-arranged trading plan, which enhances transparency and reduces concerns about opportunistic insider trading. |
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine tax-related transaction and does not reflect a change in the company's fundamentals or the executive's long-term view.
Key Dates
| Date | Description |
|---|---|
| 02/27/2026 | Date of transaction where shares were disposed of. |
| 03/03/2026 | Date the Statement of Changes in Beneficial Ownership was signed. |
Recommendation
holdThis Form 4 filing details a routine disposition of shares by an executive to cover tax obligations, which is a common practice and does not reflect a change in the company's fundamentals or the executive's confidence in the company. Therefore, it does not warrant a change in investment recommendation.
Keywords
AbbVie, ABBV, Form 4, insider transaction, stock sale, executive compensation, tax withholding, Nicholas Donoghoe
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.